Semaglutide & Empagliflozin May Treat Obesity-Related Cognitive Impairment (Mouse Study)
Obesity now affects over 650 million adults globally and is a major risk factor for various chronic diseases including cognitive decline and impairment. Recent evidence shows a link between obesity, reduced brain volume and neuronal loss, increased dementia risk, and impaired learning, memory and cognition. Preliminary evidence suggests that weight loss drugs like semaglutide may …